The estimated Net Worth of J. Chad Brown is at least 4.33 百万$ dollars as of 30 July 2021. Mr. Brown owns over 11,106 units of Nanostring Technologies Inc stock worth over 1,169$ and over the last 7 years he sold NSTG stock worth over 2,235,609$. In addition, he makes 2,092,500$ as Senior Vice President - Sales and Marketing at Nanostring Technologies Inc.
John has made over 16 trades of the Nanostring Technologies Inc stock since 2019, according to the Form 4 filled with the SEC. Most recently he exercised 11,106 units of NSTG stock worth 197,909$ on 30 July 2021.
The largest trade he's ever made was exercising 36,888 units of Nanostring Technologies Inc stock on 15 November 2019 worth over 301,006$. On average, John trades about 6,157 units every 21 days since 2017. As of 30 July 2021 he still owns at least 11,106 units of Nanostring Technologies Inc stock.
You can see the complete history of Mr. Brown stock trades at the bottom of the page.
John Chad Brown serves as Senior Vice President - Sales and Marketing of the Company. Prior to joining our company, Mr. Brown served as the President and Head of Commercial Operations for North America for Qiagen N.V. from August 2015 to March 2016. From July 2007 until August 2015, Mr. Brown held a series of commercial leadership positions at Roche Diagnostics Corporation in the Applied Sciences and Centralized Diagnostics divisions, including as VP of Marketing and VP of Sales for Centralized Diagnostics and as the National Director of Sales for Genomic Systems. Previously, he held a series of sales leadership positions in medical device and healthcare companies, including Rotech Healthcare from March 2003 to December 2005, Apria Healthcare Group from January 1998 to March 2003, Chiron Diagnostics from January 1990 to January 1998, and Humana from January 1981 to January 1990. Mr. Brown earned his BS degree in Health Services Administration from the University of Kentucky.
As the Senior Vice President - Sales and Marketing of Nanostring Technologies Inc, the total compensation of John Brown at Nanostring Technologies Inc is 2,092,500$. There are 3 executives at Nanostring Technologies Inc getting paid more, with R. Bradley Gray having the highest compensation of 7,288,840$.
John Brown is 62, he's been the Senior Vice President - Sales and Marketing of Nanostring Technologies Inc since 2017. There are 5 older and 10 younger executives at Nanostring Technologies Inc. The oldest executive at Nanostring Technologies Inc is William Young, 75, who is the Independent Chairman of the Board.
J's mailing address filed with the SEC is 530 Fairview Ave N, Seattle, WA 98109, USA.
Over the last 11 years, insiders at Nanostring Technologies Inc have traded over 114,083,977$ worth of Nanostring Technologies Inc stock and bought 981,722 units worth 9,126,410$ . The most active insiders traders include Charles P Jr Waite、Lifesciences Ii, L.P.Clarus...、Nicholas Galakatos. On average, Nanostring Technologies Inc executives and independent directors trade stock every 16 days with the average trade being worth of 4,371$. The most recent stock trade was executed by Joseph M Beechem on 6 May 2024, trading 147,853 units of NSTG stock currently worth 15,569$.
nanostring technologies (nasdaq: nstg) is a publicly held provider of life science tools for translational research and molecular diagnostics. the company's technology enables a wide variety of basic research, translational medicine and in vitro diagnostics applications. nanostring technologies provides life science tools for translational research and molecular diagnostic products. the company's ncounter® analysis system, which has been employed in basic and translational research since it was first introduced in 2008 and cited in more than 300 peer-reviewed publications, has also now been applied to diagnostic use as the ncounter dx analysis system. the company's technology offers a cost-effective way to easily profile the expression of hundreds of genes, mirnas, or copy number variations, simultaneously with high sensitivity and precision. the company's technology enables a wide variety of basic research and translational medicine applications, including biomarker discovery and vali
Nanostring Technologies Inc executives and other stock owners filed with the SEC include: